{"id":22669,"date":"2021-11-16T08:57:14","date_gmt":"2021-11-16T14:57:14","guid":{"rendered":"https:\/\/saluddigital.com\/?p=22669"},"modified":"2025-10-21T11:29:47","modified_gmt":"2025-10-21T17:29:47","slug":"se-realizan-los-primeros-ensayos-clinicos-de-terapia-contra-covid-19-desarrollada-con-inteligencia-artificial","status":"publish","type":"post","link":"https:\/\/saluddigital.com\/en\/big-data\/se-realizan-los-primeros-ensayos-clinicos-de-terapia-contra-covid-19-desarrollada-con-inteligencia-artificial\/","title":{"rendered":"The first clinical trials of therapy against COVID-19 developed with Artificial Intelligence are carried out"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

A few months ago researchers and scientists from Louisiana State University (LSU) through the Department of Computer Science created the DeepDrug AI platform<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Through LSU's DeepDrug platform, it was possible for scientists to discover an oral treatment against COVID-19, which also managed to reduce the time and cost of drug discovery by up to 90%.<\/p>

However, the only evidence has been through predictive AI studies, and some animal cell studies conducted by the Illinois Institute of Technology. Therefore, currently, Skymount Medical and the Riverside University Health System (RUHS) have begun clinical trials to test the LSU therapy.<\/p>

Testing will take place at the RUHS Comparative Effectiveness and Clinical Outcomes Research Center (CECORC) facility in Moreno Valley, California. The trial consists of evaluating the combined effects of an anticancer drug and an antiparasitic agent, both authorized for human use by the United States Food and Drug Administration (FDA).<\/p>

Studies in animal cells have achieved an effectiveness of up to 97% in reducing SARS-CoV-2, the virus that causes COVID-19.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cWe are excited to partner with RUHS and Dr. Bruce Weng's team to facilitate human clinical research to try to demonstrate the drug combination's safety and efficacy in adult patients who have tested positive for COVID-19 and exhibit high risk of infection. mild to moderate symptoms,\u201d explained Dr. Kishor Wasan, chief medical and scientific officer of Skymount Medical.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The general objective of the study is to find out what impact this combined therapy can have on reducing symptoms of COVID-19 and their severity. The scientists also hope that the trial will confirm that the combination of these drugs does not result in negative side effects.<\/p>

Finally, Dr. Weng, an infectious disease physician at RUHS Medical Center, explained that unfortunately in California with a large number of confirmed COVID-19 cases, they can do this type of study to take advantage of the data: \u201cThe only A silver lining in this is that the sample size in our hospital is substantial enough to produce valuable data when evaluating the safety and efficacy of this drug combination. This is a pilot study and voluntary 100%. The safety of our patients is paramount and we will stay in constant contact with those who choose to participate to ensure their health and well-being."<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t BIBLIOGRAPHY<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

AIMED <\/strong><\/p>

https:\/\/ai-med.io\/more-news\/clinical-trial-for-covid-19-therapeutics-discovered-using-ai\/<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Hace unos meses investigadores y cient\u00edficos de la Universidad Estatal de Luisiana (LSU) a trav\u00e9s del Departamento de Ciencias de la Computaci\u00f3n crearon la plataforma de IA DeepDrug A trav\u00e9s de la plataforma DeepDrug de la LSU fue posible que cient\u00edficos descubrieran un tratamiento oral contra COVID-19, que adem\u00e1s logr\u00f3 reducir el tiempo y el costo de descubrimiento de los f\u00e1rmacos hasta en un 90%. Sin embargo, las \u00fanicas pruebas han sido realizada a trav\u00e9s de estudios predictivos de IA, y algunos estudios con c\u00e9lulas animales que realiz\u00f3 el Instituto de Tecnolog\u00eda de Illinois. Por ello, actualmente, Skymount Medical y de El Sistema de Salud de la Universidad Riverside (RUHS) han comenzado a realizar ensayos cl\u00ednicos para probar la terapia de la LSU. Las pruebas se realizar\u00e1n en las instalaciones del Centro de Investigaci\u00f3n de Resultados Cl\u00ednicos y Efectividad Comparativa (CECORC) del RUHS en Moreno Valley, California. El ensayo consiste en evaluar los efectos combinados de un medicamento contra el c\u00e1ncer y un agente antiparasitario, ambos autorizados para uso humano por la Administraci\u00f3n de Medicamentos y Alimentos de Estados Unidos (FDA). Los estudios en c\u00e9lulas animales han logrado una efectividad de hasta 97% en la reducci\u00f3n de SARS-CoV-2, el virus que provoca el COVID-19. \u201cEstamos entusiasmados de asociarnos con RUHS y el equipo del Dr. Bruce Weng para facilitar una investigaci\u00f3n cl\u00ednica en humanos para tratar de demostrar la seguridad de la combinaci\u00f3n de medicamentos y la eficacia en pacientes adultos que han dado positivo por COVID-19 y exhiben de leve a moderado s\u00edntomas\u201d, explic\u00f3 el Dr. Kishor Wasan, director m\u00e9dico y cient\u00edfico de Skymount Medical. El objetivo general del estudio es conocer cu\u00e1l es el impacto que puede tener esta terapia combinada en la disminuci\u00f3n de s\u00edntomas de COVID-19 y la gravedad de los mismos. Los cient\u00edficos tambi\u00e9n esperan que el ensayo confirme que la combinaci\u00f3n de estos medicamentos no resulte en efectos secundarios negativos. Finalmente, el Dr. Weng, m\u00e9dico de enfermedades infecciosas del RUHS Medical Center explic\u00f3, que desafortunadamente en California al tener una gran cantidad de casos de COVID-19 confirmados, pueden realizar este tipo de estudio para sacar provecho de los datos: \u201cEl \u00fanico lado positivo en esto es que el tama\u00f1o de la muestra en nuestro hospital es lo suficientemente sustancial como para producir datos valiosos al evaluar la seguridad y eficacia de esta combinaci\u00f3n de medicamentos. Este es un estudio piloto y 100% voluntario. La seguridad de nuestros pacientes es primordial y nos mantendremos en contacto constante con quienes elijan participar para garantizar su salud y bienestar\u201d. BIBLIOGRAF\u00cdA AIMED https:\/\/ai-med.io\/more-news\/clinical-trial-for-covid-19-therapeutics-discovered-using-ai\/<\/p>","protected":false},"author":1,"featured_media":22671,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[156,3393,160],"tags":[145],"class_list":["post-22669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-big-data","category-inteligencia-artificial-y-ciencia","category-noticias","tag-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/22669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/comments?post=22669"}],"version-history":[{"count":0,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/22669\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media\/22671"}],"wp:attachment":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media?parent=22669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/categories?post=22669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/tags?post=22669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}